-
WHAT HTA BODIES CRITICIZE IN INDIRECT TREATMENT COMPARISONS FOR ADVANCED CANCERS: A THEMATIC ANALYSIS OF RECENT HTA REPORTS IN SOLID TUMORS
Mar 18, 2026, 21:38 PM -
ENHANCING ONCOLOGY REAL WORLD DATA QUALITY THROUGH CLINICALLY RELEVANT EDIT CHECKS IN A LARGE US COMMUNITY ONCOLOGY DATABASE
Mar 18, 2026, 21:38 PM -
DETERMINING AN ECONOMICALLY JUSTIFIABLE PRICE FOR TRONTINEMAB IN EARLY ALZHEIMER’S DISEASE
Mar 18, 2026, 21:38 PM -
REAL WORLD EVIDENCE FOR LABEL EXPANSION: IDENTIFYING OFF-LABEL USE TRENDS IN THE HOSPITAL SETTING
Mar 18, 2026, 21:38 PM -
CLINICAL UNMET NEEDS AND NON-INVASIVE TREATMENT PREFERENCES IN HISL MANAGEMENT: A MIXED-METHODS STUDY IN CHINA
Mar 18, 2026, 21:38 PM -
EFFECTIVE COVERAGE OF STOMACH CANCER PREVENTION IN CHILE 2009-2024
Mar 18, 2026, 21:38 PM -
EARLY PERSPECTIVES ON HEALTH TECHNOLOGY ASSESSMENT IN THE KINGDOM OF SAUDI ARABIA: EXPLORATORY SURVEY INTO MARKET ACCESS IMPLICATIONS
Mar 18, 2026, 21:38 PM -
A STRUCTURED FRAMEWORK FOR SAMPLING STRATEGY DESIGN IN LARGE-SCALE REAL-WORLD CHART REVIEW STUDIES
Mar 18, 2026, 21:38 PM -
EXPLORING BURDEN IN RARE DISEASES: EXAMINING NEUROPSYCHOLOGICAL SYMPTOMS, FLARES, AND SLEEP QUALITY
Mar 18, 2026, 21:38 PM -
INCORPORATING REAL-WORLD EVIDENCE (RWE) USING A REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) AUGMENTS TRADITIONAL SLRS: CASE STUDY IN NON-SMALL-CELL LUNG CANCER (NSCLC)
Mar 18, 2026, 21:38 PM -
INTERPRETABLE MACHINE LEARNING TO PREDICT CATASTROPHIC HEALTH EXPENDITURE RISK IN CHINA: EVIDENCE FROM NATIONALLY REPRESENTATIVE SURVEY DATA
Mar 18, 2026, 21:38 PM -
SAFETY OF SEPIAPTERIN AND PEGVALIASE FOR THE TREATMENT OF PHENYLKETONURIA (PKU): A SIMULATED TREATMENT COMPARISON (STC)
Mar 18, 2026, 21:38 PM -
COMPARATIVE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN
Mar 18, 2026, 21:38 PM -
NATURAL HISTORY, MANAGEMENT, AND BURDEN OF DISEASE IN ADULTS WITH NF1 AND SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN FRANCE
Mar 18, 2026, 21:38 PM -
USE OF PRIOR AUTHORIZATION, STEP THERAPY, AND QUANTITY LIMITSIN THE UNITED STATES: A NATIONAL PHARMACY CLAIMS ANALYSIS
Mar 18, 2026, 21:38 PM -
MEASURING ADHERENCE TO, AND PERSISTENCE WITH, ADVANCED THERAPY IN PATIENTS WITH LUPUS NEPHRITIS IN THE REAL-WORLD SETTING
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE HEALTH-RELATED QUALITY OF LIFE BURDEN IN CHRONIC HEPATITIS DELTA INFECTION: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
COST OF CARE AND BUDGET IMPACT OF FIRST-LINE (1L) TREATMENTS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FROM THE MEXICAN PUBLIC PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
DISABILITY AND ADHERENCE TO GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS AMONG U.S. ADULTS WITH DIABETES: EVIDENCE FROM THE MEDICAL EXPENDITURE PANEL SURVEY
Mar 18, 2026, 21:38 PM
